News

Primer Capital founders, Dmitry Sharov and Timur Avdeenko shared the story of the fund in a feature story by Forbes Russia.

Primer Capital COO Elizaveta Rozhdestvenskaya spoke at the round table on Investing in Science during the III International Medical Investment Forum 2019.

Acticor Biotech, Primer Capital's portfolio unit, a clinical stage biotechnology company involved in the acute phase of thrombotic diseases, including acute ischemic stroke, today announced that it has raised €7 million in addition to its Series B which is now completed at €22,3 million.

In her interview for Rusbase Primer Capital COO Elizaveta Rozhdenstvenskaya shared her thoughts on the pharma and biotech startups and the overall venture market trends.

Anton Lavrentev took part in the discussion on the “Direct and Venture Investment Funds as a Key Tool in Financing Digital Economy” held by the Analytics Center for the Government of the Russian Federation.

Primer Capital Venture Fund invested in a US-based company. The startup’s unique technology allows to halt the development of the short memory impairment that is characteristic of the patients with various neurodegenerative diseases. The portfolio of Primer Capital now includes 11 projects from Russia, USA, Israel and France.

Primer Capital investment analyst Sofia Yartseva elaborated on the role of venture investments in drug development process and its further marketing.

Primer Capital has been awarded the Best Biotech VC Fund – Europe by Wealth & Money Management Awards 2019.

The founder of Data MATRIX (Primer Capital's portfolio project) entered the ranking of the top 20 most successful MedTech entrepreneurs according to RusBase. 

Anton Lavrentev, head of the legal department at Primer Capital, in his interview for VC.ru talked about ethical components which are essential for investors to consider before taking on new target.